X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Margins improve, sales lacklustre - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis: Margins improve, sales lacklustre

May 2, 2002

Novartis India has ended FY02 on an encouraging note. While sales represent a 7% rise, net profit has grown at a faster pace thanks to a rise in operating margins, lower interest cost and positive impact from the closure of the loss making Ciba Vision operations. A sustained rise in margins for all the four quarters of the current year was ensured on the back of better price realisations, control over input costs and re-launch of its key brands.

(Rs m) FY01 FY02 Change
Sales 4,384 4,677 6.7%
Other Income 299 389 30.2%
Expenditure 3,849 4,028 4.6%
Operating Profit (EBDIT) 535 650 21.5%
Operating Profit Margin (%) 12.2% 13.9%  
Interest 122 32 -73.4%
Depreciation 100 86 -14.1%
Profit before Tax 612 921 50.4%
Tax 194 268 37.9%
Profit after Tax/(Loss) 418 653 56.1%
Net profit margin (%) 9.5% 14.0%  
No. of Shares (eoy) (m) 32.0 32.0  
Diluted Earnings per share* 13.1 20.4  
P/E (at current price)   13.5  

Operating margins for the year would have been higher but for Rs 47 m incurred on VRS and Rs 23 m provided for on account of change in accounting policy for gratuity. Further, other expenditure included Rs 16.6 m provision towards dimunition in the value of investments in US 64. But for these, operating margins would have been 15.7% for FY02, a rise of 350 basis points. Other income however, includes Rs 169 m on account of profit on sale of property at Goregaon.

% of sales FY01 FY02
Raw Materials 4.1% 3.3%
Staff Costs 8.0% 9.8%
Purchase of finished goods 49.3% 46.3%

"Pharma sales for the period closed at Rs 2,678 m registering a growth of 7.4% over the previous period. Growth was impacted by lower sales of the company’s transplant and oncology range of products.

In late 2001, the company has carved out the Biochemie segment from the existing pharma business to align the portfolio with that of the parent company. The Biochemie sector primarily focuses on the therapeutic segments of Anti-TB, Anti-DUB (gynaecology) Anti-histamines, Antibiotics, Anti-ulcerants, Anti-diabetes and Cardiovascular. This sector registered sales of Rs 1,220 m which were almost at the same level as prior year sales. On a like to like basis (pharma and Biochemie division consolidated), the company has grown 5%, underperforming industry growth rates due to absence of new products. "

Consumer Healthcare achieved 11% growth over last year largely driven by its popular OTC brand Calcium Sandoz. An encouraging growth in animal health care business was primarily driven by intensive marketing efforts in cattle and poultry segments and addition of three new licenced-in products in the cattle segment.

Table Showing Segmentwise operating margins
FY02 Sales (Rs m) % Growth Margins %*
Pharma 2,678 7.4% 19.0%
Biochemie 1,220 - 15.1%
Consumer Health 416 10.7% 6.4%
Animal Healthcare Business 363 19.2% 18.1%
*- Profit before interest and tax      

At the current market price of Rs 276, the stock trades at 14x its FY02 earnings. The stock is likely to see upside due to attractive forward valuations. We expect the margins of the company to improve further, both due to good performance of its key products and further, restructuring benefits. However, dependence on imports and growth in pharma business, remain key areas of concern.


Equitymaster requests your view! Post a comment on "Novartis: Margins improve, sales lacklustre". Click here!

  

More Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


May 17, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS